The global facial erythema treatment market is expected to be valued at US$ 299 million by 2032, up from US$ 173.3 million in 2022, growing at a 5.1% CAGR during the forecast period.
The growing patient population, large pipeline drugs, and other factors are likely to drive up demand for facial erythema treatment. However, strict government regulations governing drug product approvals are expected to stymie global market growth.
On the contrary, increasing Research and Development activities and advancements in drug products are projected to provide manufacturers with more opportunities.
Clinic applications are expected to grow significantly during the forecast period due to rising practitioner awareness of early detection and efficient treatments that do not require any kind of invasive procedures or surgeries. Patients with mild cases, or those who are uncomfortable visiting healthcare facilities for treatment, are more likely to prefer at-home care.
| Attributes | Details |
|---|---|
| Facial Erythema Treatment Market Size (2022) | US$ 173.3 Million |
| Facial Erythema Treatment Market Size (2032) | US$ 299 Million |
| Facial Erythema Treatment Market CAGR | 5.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The steadily rising use of alcohol, cigarettes, and other narcotics may result in a variety of skin diseases. Furthermore, changing climatic conditions, the introduction of new products, and allergic reactions all contribute to skin abnormalities such as rosacea, which increases the use of facial erythema treatment.
The demand for minimally invasive procedures is increasing due to advantages such as shorter recovery time and less pain post-procedure. Furthermore, people are becoming increasingly aware of the various types of facial erythema treatment options available on the market. These are important factors that are expected to drive market growth.
People have a growing desire to improve their appearance, especially if they have skin conditions like perioral dermatitis, systemic illness, or rosacea. These, along with the need for skin cancer protection, are expected to significantly drive demand for facial erythema treatment.
Certain medications used during the treatment of facial erythema may cause side effects. Antibiotics, for example, can cause bloating, abdominal pain, loss of appetite, and other side effects. This factor is likely to limit the use of this type of treatment.
In contrast, due to varying utilization demands, key manufacturers are primarily focusing on new product solutions for specific applications. During the forecast period, these factors are expected to generate creative opportunities for market share and increase demand for facial erythema treatment.
Principal Consultant
North America is the most dominant facial erythema treatment market, accounting for 42% of total revenue. This is due to the majority of the population having fair skin and being prone to skin problems, resulting in the treatment's early adoption.
Climate changes, as well as population lifestyle changes, contribute to a variety of skin diseases. Furthermore, there has been an increase in skin treatment awareness in this region. These factors are likely to sustain the region's growing demand for facial erythema treatment and boost the global market growth.
The US government spends a lot of money on pharmaceuticals and medical devices every year, and they raise awareness in society. Furthermore, the business of the facial erythema treatment market is endorsed by the collaboration of multiple international companies with a slew of major hospital chains.
With revenue of 33.7%, Europe is the second-largest facial erythema treatment market. This is due to rising alcohol consumption and extensive research and development activities in the region.
Most cases of facial erythema, such as rosacea, have no known cause or treatment. It does, however, cause significant discomfort to those who suffer from these skin conditions. In many cases, it causes extreme embarrassment, anxiety, and depression. As a result, start-up companies are taking these issues into account and devising solutions to reduce their prevalence, fueling the growth of the facial erythema treatment market.
Dr. Wladis and Dr. Adam founded Praxis Biotechnology in response to a lack of rosacea treatment options. Praxis Biotechnology is based at Albany Medical College. Praxis Biotechnology was recently awarded $50,000 after winning FuzeHub's commercialization competition. This medication, according to the non-profit, could benefit millions of people.
Legit Health is a Spanish start-up that offers a skin diagnostic tool. The startup's software employs artificial intelligence to classify 139 skin pathologies, with a focus on the detection of seven of these, including acne, rosacea, and dermatitis. The software's algorithms automatically fill in most medical grading systems for the seven skin conditions.
The team at this UK start-up develops an evidence-based treatment and delivers it monthly. The web-based platform of the start-up assists patients in developing relationships with medical professionals and seeking expert assistance when necessary. The company also develops treatments for acne, facial erythema, anti-aging, pigmentation, and melasma.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Due to the involvement of several established players, the market share for facial erythema treatment is highly competitive. These players are focusing on expanding their presence through acquisitions, expansions, product approvals, and launches in order to capitalize on market growth opportunities.
Latest Developments:
Other Market Participants of the Facial Erythema Treatment Market:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.1% from 2022 to 2032 |
| The base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments Covered | Drug Type, Disease Type, Distribution Channel, and Region. |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia, and New Zealand |
| Country scope | United States of America; Canada; Mexico; Germany; United Kingdom; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Anacor Pharmaceuticals Inc., Astellas Pharma Inc., Galderma S.A., Meda Pharmaceuticals, Pfizer Inc., Novartis International AG, Regeneron Pharmaceuticals Inc., Sanofi S.A., Valeant Pharmaceuticals International Inc., Bausch Health Companies Inc., GlaxoSmithKline plc, Merck & Co. Inc., Enzon Pharmaceuticals, etc. |
| Customization scope | Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The facial erythema treatment market is likely to accumulate a CAGR of 5.1%, during the forecast period.
North America is the leading facial erythema treatment market with revenue of 42%.
By 2032, the facial erythema treatment market is likely to grow to a valuation of US$ 299 Million.
1. Executive Summary | Facial Erythema Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2022 to 2032
5.3.1. Emollients
5.3.2. Antihistamines
5.3.3. Antifungal
5.3.4. Antibiotics
5.3.5. Corticosteroids
5.3.6. Calcineurin inhibitors
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Drug Type, 2022 to 2032
6. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032
6.3.1. Erythematotelangiectatic (ETR)
6.3.2. Papulopustular (PPR)
6.3.3. Phymatous
6.3.4. Ocular
6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Disease Type, 2022 to 2032
7. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032
8. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Drug Type
9.2.3. By Disease Type
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Disease Type
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Type
10.2.3. By Disease Type
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Disease Type
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Type
11.2.3. By Disease Type
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Disease Type
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Type
12.2.3. By Disease Type
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Disease Type
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Type
13.2.3. By Disease Type
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Disease Type
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Type
14.2.3. By Disease Type
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Disease Type
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa
15.2.2. By Drug Type
15.2.3. By Disease Type
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Disease Type
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Analysis
16.1. United States of America
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Drug Type
16.1.2.2. By Disease Type
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Drug Type
16.2.2.2. By Disease Type
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Drug Type
16.3.2.2. By Disease Type
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Drug Type
16.4.2.2. By Disease Type
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Drug Type
16.5.2.2. By Disease Type
16.5.2.3. By Distribution Channel
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2021
16.6.2.1. By Drug Type
16.6.2.2. By Disease Type
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2021
16.7.2.1. By Drug Type
16.7.2.2. By Disease Type
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2021
16.8.2.1. By Drug Type
16.8.2.2. By Disease Type
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2021
16.9.2.1. By Drug Type
16.9.2.2. By Disease Type
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2021
16.10.2.1. By Drug Type
16.10.2.2. By Disease Type
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2021
16.11.2.1. By Drug Type
16.11.2.2. By Disease Type
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2021
16.12.2.1. By Drug Type
16.12.2.2. By Disease Type
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2021
16.13.2.1. By Drug Type
16.13.2.2. By Disease Type
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2021
16.14.2.1. By Drug Type
16.14.2.2. By Disease Type
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2021
16.15.2.1. By Drug Type
16.15.2.2. By Disease Type
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2021
16.16.2.1. By Drug Type
16.16.2.2. By Disease Type
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2021
16.17.2.1. By Drug Type
16.17.2.2. By Disease Type
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2021
16.18.2.1. By Drug Type
16.18.2.2. By Disease Type
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2021
16.19.2.1. By Drug Type
16.19.2.2. By Disease Type
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2021
16.20.2.1. By Drug Type
16.20.2.2. By Disease Type
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2021
16.21.2.1. By Drug Type
16.21.2.2. By Disease Type
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Type
17.3.3. By Disease Type
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Anacor Pharmaceuticals Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Astellas Pharma Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Galderma S.A.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Meda Pharmaceuticals
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Novartis International AG
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Pfizer Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Regeneron Pharmaceuticals Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Sanofi S.A.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Valeant Pharmaceuticals International, Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Merck and Co. Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Facial Erythema Treatment Market
